Form 4: Organogenesis Holdings Inc. Executive Reports Stock Transaction
SEC Form 4 Filing
Robert Cavorsi, Vice President of Strategy at Organogenesis Holdings Inc., reports a transaction involving Class A Common Stock on March 1, 2025.
Summary
- Robert Cavorsi, Vice President of Strategy at Organogenesis Holdings Inc., filed a Form 4 with the SEC.
- The form reports a transaction involving Class A Common Stock on March 1, 2025.
- Cavorsi disposed of 667 shares at a price of $6.21.
- Following the transaction, Cavorsi beneficially owns 189,796 shares of Class A Common Stock directly.
Sentiment
Score: 5
Explanation: This is a neutral filing of a stock transaction. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects an insider's decision to sell a small portion of their holdings.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of transaction (disposal of shares). |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.